Hsbc Holdings PLC Sells 52,264 Shares of Natera, Inc. $NTRA

Hsbc Holdings PLC trimmed its holdings in Natera, Inc. (NASDAQ:NTRA) by 33.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 105,005 shares of the medical research company’s stock after selling 52,264 shares during the period. Hsbc Holdings PLC’s holdings in Natera were worth $24,170,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Reflection Asset Management acquired a new position in shares of Natera during the 4th quarter worth approximately $29,000. Palladiem LLC acquired a new stake in Natera during the 4th quarter valued at $31,000. Horizon Investments LLC acquired a new stake in Natera during the 3rd quarter valued at $32,000. Bank of Jackson Hole Trust boosted its position in Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new position in Natera during the fourth quarter worth $39,000. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

NTRA has been the topic of several research analyst reports. Royal Bank Of Canada assumed coverage on shares of Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price objective on the stock. Wells Fargo & Company lifted their target price on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Guggenheim upped their price target on shares of Natera from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, June 29th. William Blair assumed coverage on shares of Natera in a report on Tuesday, April 14th. They issued an “outperform” rating on the stock. Finally, Sanford C. Bernstein initiated coverage on Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $262.00.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 41,124 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the transaction, the chief executive officer directly owned 108,743 shares in the company, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the transaction, the director directly owned 6,183 shares in the company, valued at approximately $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 178,872 shares of company stock valued at $39,627,696 in the last three months. Insiders own 5.05% of the company’s stock.

Natera Price Performance

NTRA stock opened at $283.80 on Tuesday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $288.04. The stock has a market capitalization of $40.64 billion, a price-to-earnings ratio of -174.11 and a beta of 1.51. The business’s fifty day moving average price is $221.45 and its two-hundred day moving average price is $217.64.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.